Dartmouth-Hitchcock study compares standard against newer treatment in women whose breast cancer has spread
- Posted: December 10, 2012
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival. This study was presented today by scientists from the Dartmouth-Hitchcock and Norris Cotton Cancer Center in Lebanon, N.H., during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.